» Articles » PMID: 29263756

Osteonecrosis Following Treatment for Childhood Acute Lymphoblastic Leukaemia: The Southampton Children's Hospital Experience

Overview
Journal J Child Orthop
Publisher Sage Publications
Specialty Pediatrics
Date 2017 Dec 22
PMID 29263756
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine the prevalence of osteonecrosis (ON) in children following treatment of acute lymphoblastic leukaemia (ALL), characterise these cases and review treatment methods.

Methods: All children diagnosed and treated for ALL between 01 January 2003 and 31 December 2013 at our centre were retrospectively reviewed. Logistic regression was used to investigate risk factors for ON occurrence.

Results: Of 235 children treated for ALL, 48/235 (20.4%) children suffered musculoskeletal symptoms necessitating radiological investigation. A total of 13 (5.5%) had MRI-diagnosed ON, with a median diagnosis time of 12 months (interquartile range 10 to 14) following initiation of chemotherapy.ON affected 40 joints in 13 children. The most commonly involved joints were hips (14 joints in eight patients) and knees (12 joints in seven patients).Older age at ALL diagnosis was associated with significantly increased risk of development of ON per year (odds ratio 1.35, 95% confidence interval 1.17 to 1.57, p < 0.001).Eight children underwent at least one surgical intervention. Joint arthroplasty was undertaken in nine joints of four children at a mean age of 18.3 years. All patients who underwent hip arthroplasty had previously received core decompression, with a mean time of 27.8 months (18 to 33) between treatments.

Conclusions: ON is a significant complication of ALL treatment. Our results suggest risk stratification for development of ON by age, and targeted monitoring of high-risk joints is possible. ON treatment is varied with little evidence base.

Citing Articles

Osteonecrosis in Korean Paediatric and Young Adults with Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma: A Nationwide Epidemiological Study.

Hahn S, Lee M, Huser A, Gim Y, Kim E, Kim M J Clin Med. 2022; 11(9).

PMID: 35566613 PMC: 9105090. DOI: 10.3390/jcm11092489.


Genetic polymorphism of vitamin D receptors and plasminogen activator inhibitor-1 and osteonecrosis risk in childhood acute lymphoblastic leukemia.

Sherief L, Beshir M, Raafat N, Abdelkhalek E, Mokhtar W, Elgerby K Mol Genet Genomic Med. 2021; 9(7):e1700.

PMID: 34042331 PMC: 8372120. DOI: 10.1002/mgg3.1700.

References
1.
Tsukanaka M, Halvorsen V, Nordsletten L, Engesaeter I, Engesaeter L, Fenstad A . Implant survival and radiographic outcome of total hip replacement in patients less than 20 years old. Acta Orthop. 2016; 87(5):479-84. PMC: 5016906. DOI: 10.1080/17453674.2016.1212180. View

2.
Vora A . Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia. Br J Haematol. 2011; 155(5):549-60. DOI: 10.1111/j.1365-2141.2011.08871.x. View

3.
Seibel N, Steinherz P, Sather H, Nachman J, Delaat C, Ettinger L . Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2007; 111(5):2548-55. PMC: 2254538. DOI: 10.1182/blood-2007-02-070342. View

4.
Marker D, Seyler T, Ulrich S, Srivastava S, Mont M . Do modern techniques improve core decompression outcomes for hip osteonecrosis?. Clin Orthop Relat Res. 2008; 466(5):1093-103. PMC: 2311489. DOI: 10.1007/s11999-008-0184-9. View

5.
Mattano Jr L, Sather H, Trigg M, Nachman J . Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000; 18(18):3262-72. DOI: 10.1200/JCO.2000.18.18.3262. View